Drug intelligence / Profile preview

LF-CAR-020

Development stage: Unknown
Lead developer: Shanghai LIFE Medical Science and Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

LF-CAR-020 is a chimeric antigen receptor (CAR) cell therapy being developed by Shanghai LIFE Medical Science and Technology for the treatment of solid tumors. The therapy involves the genetic modification of immune cells (typically T cells) using a lentiviral vector to express a CAR directed against a specific, though currently undisclosed, tumor-associated antigen. By engineering the patient's immune cells to recognize and attack malignant cells, LF-CAR-020 aims to provide a targeted immunotherapy for various solid malignancies. It is currently undergoing Phase 1 clinical evaluation.

Beyond the preview

Go deeper on LF-CAR-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LF-CAR-020.

Explore the full profile